ClinicalTrials.gg
CompletedNCT06063109Updated Nov 22, 2023

A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.

A Phase 1 interventional study of THP-00101 (Dapagliflozin) 10mg and THP-00102 (Telmisartan) 80mg in Hypertension and Diabetes Mellitus, Type 2, sponsored by THPharm Corp.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by THPharm Corp. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing dapagliflozin in Hypertension — 1 open to participants now, 3 under way, 2 of them phase 3. dapagliflozin · Hypertension.

Enrollment
6th of 10
51 · median 106
Started
2023
the only one that year
Phase 1
Only one
of the 10
Registered
6th of 10
by date
Lead sponsor
1 of 10
THPharm Corp.

Among the 10 studies testing dapagliflozin in Hypertension, this one is the 6th largest by enrollment, is the only one that started in 2023, is the only one in phase 1, and was the 6th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 10 studies testing dapagliflozin in Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dapagliflozin in Hypertension, or all of them as a file.
02

Study summary

The study was designed to evaluate the safety and pharmacokinetic interaction between THP-00101 and THP-00102 in healthy adult volunteers.

Read the detailed description

The study consists of 2 periods of THP-00101 or THP00102 administration over 5 days and combined administration of THP-00101 and THP00102 over 5 days in two arms.

Dapagliflozin (18 Subjects): Tx A (5 days) -> Tx B (5 days) Treatment A: THP-00101 (Dapagliflozin) 1 tablet/5 days Treatment B: THP-00101 (Dapagliflozin) 1 tablet/5 days + THP-00102 (Telmisartan) 1 tablet/5 days

Telmisartan (32 Subjects): Tx C (5 days) -> Tx C (5 days) Treatment C: THP-00102 (Telmisartan) 1 tablet/5 days Treatment B: THP-00102 (Telmisartan) 1 tablet/5 days + THP-00101 (Dapagliflozin) 1 tablet/5 days

03

Conditions studied

  • Hypertension
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A person who is 19 years of age or older at the screening visit
  2. A person who weighs at least 55 kg (50 kg for women) and has a (BMI) of at least 18.0 kg/m2 and at least 30.0 kg/m2 at screening visit

    ☞ BMI (kg/m2) = Weight (kg)/ {Height (m)}2

  3. A person who has no congenital or chronic disease and has no pathological symptoms or findings as a result of medical examination at a screening visit
  4. A person who has been determined to be suitable for the test as a result of diagnostic tests such as hematology tests, hematochemical tests, serum tests, urine tests, etc., set and conducted by the test manager (or delegated test doctor) according to the characteristics of clinical drugs
  5. A person who agrees to exclude the possibility of pregnancy using a medically recognized method* (except hormones) and does not provide sperm or eggs from the date of first administration of the clinical trial drug to 14 days after the date of last clinical trial drug administration

    *medically-accepted Contraceptive methods: a combination of intrauterine devices, vasectomy, tubular ligation, and blocking contraception (male condoms, female condoms, cervical caps, contraceptive septum, sponge, etc.) or a combination of two or more blocking contraceptives

  6. A person who has received and understood sufficient explanation of the purpose, contents, characteristics of clinical trial drugs, expected abnormal cases, etc., and signed the consent form according to his/her free will

Exclusion criteria

Exclusion Criteria:

  1. A person who has or has a history of diseases corresponding to the digestive system, cardiovascular system, endocrine system, respiratory system, blood and tumor, infectious disease, kidney and urinary system, mental and nervous system, musculoskeletal system
  2. A person who has a history of gastrointestinal surgery (excluding simple appendectomy or hernia surgery) or has gastrointestinal diseases that may affect drug absorption
  3. Those who have taken drug metabolism-inducing and inhibiting drugs such as barbital drugs within one month of the first administration date, or drugs that may interfere with this clinical trial within 10 days of the first administration (however, in consideration of pharmacokinetic and pharmacokinetic characteristics of combination drugs it may consider as possible)
  4. A person who participates in other clinical trials or biological equivalence tests within six months of the first administration and administered clinical trial drugs
  5. A person who has donated whole blood within 8 weeks of the first administration, donated ingredients within 2 weeks or received a blood transfusion within 4 weeks from the first administration
  6. A person who meets the following conditions within one month of the first dose date

    • Men consume an average of 21 cups/week of alcohol
    • Women consume an average of 14 cups/week of alcohol

      (1 glass = 50mL of soju, 30mL of spirits, or 250mL of beer)

    • An average of more than 20 cigarettes a day
  7. A patient who falls under the following

    • Patients with a history of to the main ingredient or additive of this drug
    • Type 1 diabetes patient with diabetic ketoacidosis
    • Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
    • A patient on dialysis
    • Patients with severe liver disorders, biliary obstruction, or bile congestion (mostly this drug is excreted as bile). A decrease in liver cleaning rate can be expected in patients with bile congestion, biliary obstruction disease, or liver failure.)
    • Patients with hereditary angioedema, or patients with a history of angioedema when treated with ACE inhibitors or angiotensin II receptor antagonists
    • Combination with aliskiren-containing preparations in patients with diabetes or moderate to severe renal disabilities ( \<60mL/min/1.73m2)
  8. For reasons other than the above selection and exclusion criteria, the person in charge of testing (or the delegated test doctor) determines that he/she is not suitable for participation in this clinical trial
  9. In the case of female volunteers, those suspected of being pregnant or nursing
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    THP-00101 (Dapagliflozin) 10mg (18 Subjects): Tx A (5 days) -\> Tx B (5 days) Treatment A: THP-00101 (Dapagliflozin) 10mg/5 days Treatment B: THP-00101 (Dapagliflozin) 10mg/5 days + THP-00102 (Telmisartan) 80mg/5 days

    Drug: THP-00101 (Dapagliflozin) 10mg · Drug: THP-00102 (Telmisartan) 80mg

  • Experimental
    Telmisartan

    THP-00102 (Telmisartan) 80mg (32 Subjects): Tx C (5 days) -\> Tx B (5 days) Treatment C: THP-00102 (Telmisartan) 80mg/5 days Treatment B: THP-00102 (Telmisartan) 80mg/5 days + THP-00101 (Dapagliflozin) 10mg/5 days

    Drug: THP-00101 (Dapagliflozin) 10mg · Drug: THP-00102 (Telmisartan) 80mg

Interventions

  • Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B

    Also known as: Forxiga Tab. 10mg

  • Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A

    Also known as: Micardis Tab. 80mg

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - AUCτ,ss

    AUCτ,ss of Dapagliflozin \& Telmisartan

    Time frame: Day 1 to Day 11

  2. Pharmacokinetics - Cmax,ss

    Cmax,ss of Dapagliflozin \& Telmisartan

    Time frame: Day 1 to Day 11

  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Evaluate incidents rate of Adverse Event of Treatment-Emergent Adverse Event and compare concomitant medication usage

    Time frame: Day 1 to Day 17

Secondary outcomes

  1. Pharmacokinetics - Tmax,ss

    Tmax,ss of Dapagliflozin \& Telmisartan

    Time frame: Day 1 to Day 11

  2. Pharmacokinetics - Cmin,ss

    Cmin,ss of Dapagliflozin \& Telmisartan

    Time frame: Day 1 to Day 11

  3. Pharmacokinetics - CLss/F

    CLss/F of Dapagliflozin \& Telmisartan

    Time frame: Day 1 to Day 11

  4. Pharmacokinetics - Vdss/F

    Vdss/F of Dapagliflozin \& Telmisartan

    Time frame: Day 1 to Day 11

  5. Pharmacokinetics - PTF

    Peak-trough Fluctuation of Dapagliflozin \& Telmisartan

    Time frame: Day 1 to Day 11

07

Study locations

1 site
  • H Plus Yangji Hospital
    Seoul, 08779, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Nov 2023, 1 month.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 1 month is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Oct 2, 2023
StartActual
Oct 9, 2023
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 9, 2023
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063109
Lead sponsor
THPharm Corp.
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Oct 9, 2023
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023
Last update
Nov 22, 2023

Study contacts

Seung Hyun Kang, M.D
principal investigator · H Plus Yangji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Telmisartan

Start the discussion